The paper, published on May 22, sparked worldwide concern that using the anti-malarial drug hydroxychloroquine on COVID-19 patients may not be safe.

The authors said the company that provided the data, would not transfer the full dataset for an independent review and they "can no longer vouch for the veracity of the primary data sources."

An Alberta-wide trial investigating the effectiveness of hydroxychloroquine as a potential treatment for COVID-19 has been cleared to resume. However, it appears the province's success in flattening the curve will keep the Alberta HOPE trial on pause for now.

A clinical trial of hydroxychloroquine found that it wasn't more effective than a placebo at preventing COVID-19.

An influential paper that flagged dangers with using hydroxychloroquine to treat coronavirus is now being questioned.

Nayib Bukele said El Salvador was not promoting the drug anymore as a treatment, though patients would still be able to take it as a preventative measure if they wished.

A spokesperson with Alberta Health confirmed Tuesday that the "clinical trial has been temporarily suspended by the research team so they can review the literature and results from other studies."

The World Health Organization announced it has paused part of a coronavirus trial looking into a malaria drug used by Trump.

Friday’s report in the journal Lancet is not a rigorous test of hydroxychloroquine or chloroquine, but it is by far the largest look at their use in real world settings, spanning 671 hospitals on six continents.

The study seeks to determine whether chloroquine and hydroxychloroquine could play a role in the fight against the novel coronavirus.